Current views on the pathophysiology, diagnosis and treatment of immune thrombocytopenia in children

1. Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010 Mar; 85 (3): 174–180.

2. Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population- based study in France. Blood 2014 Nov 20; 124 (22): 3308–3315.

3. Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol 2010 Jun; 149 (6): 855–864.

4. Kühne T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie 2017 Jan 31; 37 (1): 36–44.

5. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 Mar 12; 113 (11): 2386–2393.

6. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011 Apr 21; 117 (16): 4190–4207.

7. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010 Jan 14; 115 (2): 168–186.

8. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019; 3 (22): 3780–3817.

9. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019 Dec 10; 3 (23): 3829–3866.

10. Smalisz-Skrzypczyk K, Romiszewski M, Matyasiak M, et al. The influence of primary cytomegalovirus or Epstein-Barr virus infection on course of idiopathic trombocytopenic purpura. Adv Exp Med Biol 2016; 878: 83–88.

11. Shah I. Immune thrombocytopenic purpura: a presentation of HIV infection. J Int Assoc Provid AIDS Care 2013; 12 (2): 95–97.

12. Zhang W, Nardi MA, Borkowsky W, et al. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 2009 Apr 23; 113 (17): 4086–4093.

13. Elalfy MS, Nugent D. Viruses, anti-viral therapy, and viral vaccines in children with immune thrombocytopenia. Semin Hematol 2016 Apr; 53 (Suppl 1): S70–S72.

14. O’Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 2012; 129 (2): 248–255.

15. Russo G, Miraglia V, Branciforte F, et al; AIEOP-ITP Study Group. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr Blood Cancer 2011; 56 (2): 273–278.

16. Treepongkaruna S, Sirachainan N, Kanjanapongkul S, et al. Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura: a multi-center randomized controlled trial. Pediatr Blood Cancer 2009; 53 (1): 72–77.

17. Al-Samkari H, Kuter DJ. Antiplatelet antibody testing in immune thrombocytopenia and Evan’s syndrome: longitudinal serological evolution and relation to clinical features. Blood 2018; 132 (Suppl 1): 1137.

18. Al-Samkari H, Rosovsky RP, Karp Leaf RS, et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv 2020; 4 (1): 9–18.

19. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003 Aug 1; 102 (3): 887–895.

20. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003 Sep; 9 (9): 1123–1124.

21. Aslam R, Segel GB, Burack R et al. Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells. Br J Haematol 2016; 173: 159–160.

22. Talaat RM, Elmaghraby AM, Barakat SS, et al. Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP). Clin Exp Immunol 2014 May; 176 (2): 291–300.

23. Morodomi Y, Kanaji S, Won E, et al. Mechanisms of anti-GPIbα antibody-induced thrombocytopenia in mice. Blood 2020 Jun 18; 135 (25): 2292–2301.

24. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 2015 Jul 17; 6: 7737.

25. Tao L, Zeng Q, Li J, et al. Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia. J Hematol Oncol 2017 Feb 8; 10 (1): 46.

26. Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008 Nov 15; 112 (10): 4003–4008.

27. Neunert CE, Buchanan GR, Imbach P, et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 2013 May 30; 121 (22): 4457–4462.

28. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015 Mar; 13 (3): 457–464.

29. Psaila B, Petrovic A, Page LK, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009 Nov 26; 114 (23): 4777–4783.

30. Elalfy M, Elbarbary N, Khaddah N, et al. Intracranial hemorrhage in acute and chronic childhood immune thrombocytopenic purpura over a ten-year period: an Egyptian multicenter study. Acta Haematol 2010; 123 (1): 59–63.

31. Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol 2015 Jul; 170 (2): 141–149.

32. Blatt J, Weston G, Gold C. Fatigue as marker of thrombocytopenia in childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2011 Feb; 27 (1): 65–67.

33. Noris P, Klersy C, Gresele P, et al. Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. Br J Haematol 2013; 162 (1): 112–119.

34. Cybulska A, Meintker L, Ringwald J, et al. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. Br J Haematol 2017; 177 (4): 612–619.

35. Almazni I, Stapley R, Morgan NV. Inherited thrombocytopenia: Update on genes and genetic variants which may be associated with bleeding. Front Cardiovasc Med 2019 Jun 19; 6: 80.

36. Heitink-Pollé KM, Nijsten J, Boonacker CW, et al. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood 2014 Nov 20; 124 (22): 3295–3307.

37. Beck CE, Nathan PC, Parkin PC, et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005 Oct; 147 (4): 521–527.

38. Heitink-Pollé KMJ, Uiterwaal CSPM, Porcelijn L, et al. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood 2018; 132 (9): 883–891.

39. Lioger B, Maillot F, Ternant D, et al. Efficacy and safety of anti-D immunoglobulins versus intravenous immunoglobulins for immune thrombocytopenia in children: Systematic review and meta-analysis of randomized controlled trials. J Pediatr 2019 Jan; 204: 225–233.

40. Bennett CM, Neunert C, Grace RF, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer 2018; 65 (1): e26736.

41. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011 Jul 7; 118 (1): 28–36.

42. Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016 Jul 2; 388 (10039): 45–54.

43. Li H, Yang H, Liu WJ. Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis. Eur Rev Med Pharmacol Sci 2018 Sep; 22 (18): 6162–6169.

44. Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of longterm treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017; 130 (23): 2527–2536.

45. Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet 2015 Oct 24; 386 (10004): 1649–1658.

46. Elgebaly AS, Ashal GE, Elfil M, et al. Tolerability and efficacy of Eltrombopag in chronic immune thrombocytopenia: Metaanalysis of randomized controlled trials. Clin Appl Thromb Hemost 2017 Nov; 23 (8): 928–937.

47. Marshall AL, Scarpone R, De Greef M, et al. Remissions after long-term use of romiplostim for immune thrombocytopenia. Haematologica 2016; 101 (12): e476–e478.

48. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol 2015; 90 (3): E40–E43.

49. Mathias SD, Li X, Eisen M, et al. A phase 3, randomized, double- blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer 2016; 63 (7): 1232–1237.

50. Grainger JD, Blanchette VS, Grotzinger KM, et al. Healthrelated quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br J Haematol 2019; 185 (1): 102–106.

51. Liang Y, Zhang L, Gao J, et al. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One 2012; 7 (5): e36698.

52. Qu M, Zhou J, Yang SJ, et al. Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis. J Int Med Res 2020 Oct; 48 (10): 300060520962348.

53. Dai WJ, Zhang RR, Yang XC, et al. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children. Eur Rev Med Pharmacol Sci 2015 Jul; 19 (13): 2379–2383.

54. Parodi E, Rivetti E, Amendola G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol 2009; 144 (4): 552–558.

55. Miano M, Ramenghi U, Russo G, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian Association of Paediatric Haematology/Oncology. Br J Haematol. 2016 Nov; 175 (3): 490–495.

56. Panigrahi A, Clark A, Myers J, et al. A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias. Pediatr Blood Cancer 2017 Feb; 64 (2): 287–293.

57. Mousavi-Hasanzadeh M, Bagheri B, Mehrabi S, et al. Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: A randomized blinded trial. Int Immunopharmacol 2020 Nov; 88: 106895.

58. Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES): A single institution‘s experience. J Pediatr Hematol Oncol 2017 Aug; 39 (6): 420–424.

59. Liu AP, Cheuk DK, Lee AH, et al. Cyclosporin A for persistent or chronic immune thrombocytopenia in children. Ann Hematol 2016 Oct; 95 (11): 1881–1886.

60. Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost 2013 Nov; 11 (11): 1946–1953.

61. Rodeghiero F. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP. Br J Haematol 2018 Apr; 181 (2): 183–195.

62. Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood 2018 Mar 15; 131 (11): 1172–1182.

63. Heitink-Pollé KM, Haverman L, Annink KV, et al. Health-related quality of life in children with newly diagnosed immune thrombocytopenia. Haematologica 2014; 99 (9): 1525–1533.

64. Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hematol 2021 Feb 1; 96 (2): 199–207.

65. Grainger JD, Young NL, Blanchette VS, et al. Quality of life in immune thrombocytopenia following treatment. Arch Dis Child 2013; 98 (11): 895–897.

66. Grainger JD, Blanchette VS, Grotzinger KM, et al. Healthrelated quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Br J Haematol 2019; 185 (1): 102–106.

67. Kumar M, Lambert MP, Breakey V, et al; ITP Consortium of North America. Sports participation in children and adolescents with immune thrombocytopenia (ITP). Pediatr Blood Cancer 2015; 62 (12): 2223–2225.

68. Howell C, Scott K, Patel DR. Sports participation recommendations for patients with bleeding disorders. Transl Pediatr 2017; 6 (3): 174–180.